Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment

Journal of Cystic Fibrosis

Volumn 13, Issue 5, 2014, Pages 534-541

  Kappler, Matthias ^a   Nagel, Felicitas ^a   Feilcke, Maria ^a   Heilig, Gabriele ^a   Grimmelt, Ann Christin ^a   Pawlita, Ingo ^a   Irnstetter, Armin ^a   Hildebrandt, Jenna ^a   Burmester, Helen ^a   Kröner, Caroline ^a   Griese, Matthias ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cystic fibrosis; Prognostic value; Pseudomonas aeruginosa; Serum antibodies

Indexed keywords

ALKALINE PROTEINASE; ANTIBODY; ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; ELASTASE; EXOTOXIN; EXOTOXIN A; FOSFOMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHILD; CYSTIC FIBROSIS; ERADICATION THERAPY; FEMALE; FOLLOW UP; HUMAN; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; FORECASTING; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROGNOSIS; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDY; TIME;

ADOLESCENT; ANTIBODIES, BACTERIAL; CYSTIC FIBROSIS; FORECASTING; HUMANS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84925936295     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.06.006     Document Type: Article

References (30)

1. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122(1):1-9.
2. Konstan M.W., Hilliard K.A., Norvell T.M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994, 150(2):448-454.
3. Pier G.B. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 2000, 97(16):8822-8828.
4. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12(3):158-161.
5. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5):581-588.
6. Jensen T., Pedersen S.S., Garne S., Heilmann C., Hoiby N., Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19(6):831-838.
7. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23(5):330-335.
8. Griese M., Muller I., Reinhardt D. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 2002, 7(2):79-80.
9. Ratjen F., Doring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358(9286):983-984.
10. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65(4):286-291.
11. Taccetti G., Campana S., Festini F., Mascherini M., Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26(3):458-461.
12. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338(8769):725-726.
13. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Doring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998, 25(2):88-92.
14. Doring G., Flume P., Heijerman H., Elborn J.S., Consensus Study G Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012 Dec, 11:461-479. [PubMed PMID: 23137712].
15. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3(2):67-91.
16. Douglas T.A., Brennan S., Berry L., Winfield K., Wainwright C.E., Grimwood K., et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax 2010, 65(11):985-990.
17. Farrell P.M., Govan J.R. Pseudomonas serology: confusion, controversy, and challenges. Thorax 2006, 61(8):645-647.
18. Kappler M., Kraxner A., Reinhardt D., Ganster B., Griese M., Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006, 61(8):684-688.
19. Milagres L.G., Castro T.L., Garcia D., Cruz A.C., Higa L., Folescu T., et al. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol 2009, 44(4):392-401.
20. Pressler T., Karpati F., Granstrom M., Knudsen P.K., Lindblad A., Hjelte L., et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009, 8(1):37-42.
21. Ratjen F., Walter H., Haug M., Meisner C., Grasemann H., Doring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007, 42(3):249-255.
22. Tramper-Stranders G.A., van der Ent C.K., Slieker M.G., Terheggen-Lagro S.W., Teding vB, Kimpen J.L., et al. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006, 61(8):689-693.
23. Anstead M., Heltshe S., Kahn U., Barbieri J.T., Langkamp M., Döring G., et al. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. J Cyst Fibros 2013, 12:147-153.
24. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
25. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Olinsky A., Phelan P.D. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996, 21(5):267-275.
26. Wainwright C.E., Vidmar S., Armstrong D.S., Byrnes C.A., Carlin J.B., Cheney J., et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011 Jul 13, 306(2):163-171. [PubMed PMID: 21750293].
27. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009, (4):CD004197. [PubMed PMID: 19821321].
28. Dolce D., Cariani L., Campana S., Ravenni N., Mergni G., Biffi A., et al. Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2014, 13(1):116-117. [1].
29. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., de Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013, 12(1):29-34.
30. Taccetti G., Bianchini E., Cariani L., Buzzetti R., Costantini D., Trevisan F., et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012, 67(10):853-859.